Filtered By:
Drug: Pravastatin

This page shows you your search results in order of relevance. This is page number 2.

Order by Relevance | Date

Total 49 results found since Jan 2013.

Long-Term Effect of Pravastatin on Carotid Intima-Media Complex Thickness Clinical Sciences
Conclusions—The usual Japanese dose of pravastatin significantly reduced the progression of carotid IMT at 5 years in patients with noncardioembolic stroke.Clinical Trial Registration—URL: http://www.clinicaltrials.gov. Unique identifier: NCT00361530.
Source: Stroke - December 22, 2017 Category: Neurology Authors: Masatoshi Koga, Kazunori Toyoda, Kazuo Minematsu, Masahiro Yasaka, Yoji Nagai, Shiro Aoki, Tomohisa Nezu, Naohisa Hosomi, Tatsuo Kagimura, Hideki Origasa, Kenji Kamiyama, Rieko Suzuki, Toshiho Ohtsuki, Hirofumi Maruyama, Kazuo Kitagawa, Shinichiro Uchiyam Tags: Risk Factors, Secondary Prevention, Ultrasound, Atherosclerosis Original Contributions Source Type: research

Mixed Results for Low-Dose Statin in Second Stroke
(MedPage Today) -- Pravastatin didn't reduce incidence of recurrent stroke, but did offer other benefits.
Source: MedPage Today Geriatrics - February 16, 2015 Category: Geriatrics Source Type: news

Pharmacological interventions for asymptomatic carotid stenosis
CONCLUSIONS: Although there is no high-certainty evidence to support pharmacological intervention, this does not mean that pharmacological treatments are ineffective in preventing ischaemic cerebral events, morbidity, and mortality. High-quality RCTs are needed to better inform the best medical treatment that may reduce the burden of carotid stenosis. In the interim, clinicians will have to use other sources of information.PMID:37565307 | DOI:10.1002/14651858.CD013573.pub2
Source: Atherosclerosis - August 11, 2023 Category: Cardiology Authors: Caroline Nb Clezar Carolina Dq Flumignan Nicolle Cassola Luis Cu Nakano Virginia Fm Trevisani Ronald Lg Flumignan Source Type: research

Associations Between Thrombin Generation and the Risk of Cardiovascular Disease in Elderly Patients: Results From the PROSPER Study
Conclusions. We demonstrate that a delayed and decreased thrombin generation is a strong and independent predictor for stroke in elderly people at increased risk of vascular disease. However, no convincing consistent association could be demonstrated between thrombin generation and incident CHD.
Source: Journals of Gerontology Series A: Biological Sciences and Medical Sciences - July 6, 2015 Category: Geriatrics Authors: Loeffen, R., Winckers, K., Ford, I., Jukema, J. W., Robertson, M., Stott, D. J., Spronk, H. M., ten Cate, H., Lowe, G. D., on behalf of the PROSPER Study Group Tags: Research Article Source Type: research

Statins cut heart deaths in men by 28% finds study
Conclusion This new analysis found that men without cardiovascular disease who were prescribed a statin were less likely to go on to develop heart disease or have a major cardiovascular event. These findings from the five-year randomised controlled trial are useful – there's been a lot of debate about whether giving statins to people without any cardiovascular disease is helpful. But it's harder to draw conclusions from the longer term results, as these were from a non-randomised observational period. Potential confounding factors – such as the men's attitude to medicine, risk and health – may have influenced the res...
Source: NHS News Feed - September 7, 2017 Category: Consumer Health News Tags: Heart/lungs Source Type: news

Mortality and Associated Morbidities Following Traumatic Brain Injury in Older Medicare Statin Users
Conclusion: These findings provide valuable information for clinicians treating older adults with TBI as clinicians can consider, when appropriate, atorvastatin and simvastatin to older adults with TBI in order to decrease mortality and associated morbidities.
Source: The Journal of Head Trauma Rehabilitation - November 1, 2018 Category: Neurology Tags: Focus on Clinical Research and Practice Source Type: research

Long-term impact on healthcare resource utilization of statin treatment, and its cost effectiveness in the primary prevention of cardiovascular disease: a record linkage study
Conclusion Five years' primary prevention treatment of middle-aged men with a statin significantly reduces healthcare resource utilization, is cost saving, and increases QALYs. Treatment of even younger, lower risk individuals is likely to be cost-effective.
Source: European Heart Journal - February 1, 2014 Category: Cardiology Authors: McConnachie, A., Walker, A., Robertson, M., Marchbank, L., Peacock, J., Packard, C. J., Cobbe, S. M., Ford, I. Tags: Prevention and epidemiology Source Type: research

Pravastatin acute neuroprotective effects depend on Blood brain barrier integrity in experimental cerebral ischemia.
Abstract Statins have since long been reported to exert acute neuroprotection in experimental stroke models. However, crucial questions still need to be addressed as far as the timing of their cerebral effects after intravascular administration and the role played by the blood brain barrier (BBB) crossing properties. We tested the effects of an hydrophilic statin (pravastatin, 100nM), which poorly crosses BBB under physiological conditions. Pravastatin was administered either 90min before or immediately after transient middle cerebral artery occlusion in the in vitro isolated guinea pig brain preparation. A multi-...
Source: Brain Research - April 23, 2015 Category: Neurology Authors: Carone D, Librizzi L, Cattalini A, Sala G, Conti E, Cuccione E, Versace A, Cai R, Monza L, de Curtis M, Ferraresea C, Beretta S Tags: Brain Res Source Type: research

New Biomarkers for Atherothrombosis in Antiphospholipid Syndrome: Genomics and Epigenetics Approaches
Conclusions In recent years, there have been many advances in the understanding of the molecular basis for vascular involvement in APS, but many areas need to be further investigated, in particular the association between altered genetic/epigenetic profiles, autoantibodies and clinical manifestations, and the effectiveness of new therapeutic strategies. It would be interesting to apply next generation sequencing technologies like RNA-Seq along with GWAS to screen both, the gene profile and the whole transcriptome of large cohorts of primary APS patients, in order to reveal the mutations/polymorphisms, post-transcriptiona...
Source: Frontiers in Immunology - April 15, 2019 Category: Allergy & Immunology Source Type: research

Risk reductions for cardiovascular disease with pravastatin treatment by dyslipidemia phenotype: A post hoc analysis of the MEGA Study.
CONCLUSION: Pravastatin therapy provided significant risk reductions for CHD and CVD in patients with phenotype IIa dyslipidemia, but not in those with phenotype IIb dyslipidemia. PMID: 23265677 [PubMed - as supplied by publisher]
Source: Journal of Cardiology - December 19, 2012 Category: Cardiology Authors: Nishiwaki M, Ikewaki K, Ayaori M, Mizuno K, Ohashi Y, Ohsuzu F, Ishikawa T, Nakamura H, for the MEGA Study Group Tags: J Cardiol Source Type: research

Long‐Term Follow‐Up of Moderately Hypercholesterolemic Hypertensive Patients Following Randomization to Pravastatin vs Usual Care: The Antihypertensive and Lipid‐Lowering Treatment to Prevent Heart Attack Trial (ALLHAT‐LLT)
The authors conducted a randomized, controlled, multicenter trial, in which they assigned well‐controlled hypertensive participants aged 55 years and older with moderate hypercholesterolemia to receive pravastatin (n=5170) or usual care (n=5185) for 4 to 8 years, when trial therapy was discontinued. Passive surveillance using national databases to ascertain deaths and hospitalizations continued for a total follow‐up of 8 to 13 years to assess whether mortality and morbidity differences persisted or new differences developed. During the post‐trial period, fatal and nonfatal outcomes were available for 98% and 64% o...
Source: The Journal of Clinical Hypertension - June 10, 2013 Category: Cardiology Authors: Karen L. Margolis, Barry R. Davis, Charles Baimbridge, Jerry O. Ciocon, Aloysius B. Cuyjet, Richard A. Dart, Paula T. Einhorn, Charles E. Ford, David Gordon, Thomas J Hartney, L. Julian Haywood, Jordan Holtzman, David E. Mathis, Suzanne Oparil, Jeffrey L. Tags: Original Paper Source Type: research